| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_143ac4fbe1e063c6a828a96cfffc34d5 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4439
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-209
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2095
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2846
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2866
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-535
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-50 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4439
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-535
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-24 |
| filingDate |
2020-09-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_45754ad79df0cee87e1ebbd35792fab1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b231376d0a664327cc117fbdc854ca72
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_59f88e73bbb3e844fc23ce2a291283b9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a6671d75d1900f6aa01bf25f8416e16f |
| publicationDate |
2021-06-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2021107370-A1 |
| titleOfInvention |
Core tablet preparation comprising proton pump inhibitor and mosapride |
| abstract |
The present invention relates to a composite preparation in a core tablet form composed of an inner core comprising as an active ingredient at least one selected from the group consisting of esomeprazole, dexlansoprazole, and rabeprazole, and an outer layer part comprising mosapride as an active ingredient and having a bilayer structure of a sustained release layer and an immediate release layer. The composite preparation maintains pharmaceutical activities of esomeprazole and mosapride for 24 hours even at a single dosage per day. |
| priorityDate |
2019-11-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |